Home › Oropharyngeal Cancer › Wisconsin › Stevens Point
Oropharyngeal Cancer clinical trials in Stevens Point, WI
3 studies for Oropharyngeal Cancer are looking for participants at sites in and around Stevens Point (within about 30 miles). Open a study to see who can join and how to contact the study team.
Recruiting for a study here? Feature it at the top of this page — $99 for 30 days →
BiCaZO: A Study Combining Two Immunotherapies (Cabozantinib and Nivolumab) to Treat Patients With Advanced Melanoma or Squamous Cell Head and Neck Cancer, an immunoMATCH Pilot Study
RecruitingPhase 2
- Marshfield Medical Center-River Region at Stevens Point, Stevens Point
Testing the Addition of the Drug BMX-001, a Radioprotector, or a Placebo to the Usual Chemoradiation Therapy for Patients With Head and Neck Cancer
RecruitingPhase 2
- Aspirus Cancer Care - Stevens Point, Stevens Point
- Aspirus Cancer Care - Wisconsin Rapids, Wisconsin Rapids · 15 mi away
Comparing Radiation Plus Cetuximab to Radiation Plus Chemotherapy in People With Head and Neck Cancer Who Cannot Receive Cisplatin
RecruitingPhase 3
- Aspirus Cancer Care - Stevens Point, Stevens Point
- Aspirus Cancer Care - Wisconsin Rapids, Wisconsin Rapids · 15 mi away
Oropharyngeal Cancer trials in other cities
- Edison, NJ8 studies
- Atlanta, GA8 studies
- Chicago, IL7 studies
- New York City, NY6 studies
- Queens, NY5 studies
- Pittsburgh, PA5 studies
- Los Angeles, CA5 studies
- St. Louis, MO5 studies
- Omaha, NE5 studies
- Kansas City, MO5 studies
- Philadelphia, PA5 studies
- Milwaukee, WI5 studies
Other studies in Stevens Point
- Lung Cancer10 studies
- Non-Small Cell Lung Cancer8 studies
- Prostate Cancer7 studies
- Head and Neck Squamous Cell Carcinoma7 studies
- Acute Myeloid Leukemia6 studies
- Colorectal Cancer5 studies
- Hypopharyngeal Cancer5 studies
- Laryngeal Cancer5 studies
- Oral Cancer5 studies
- Breast Cancer5 studies
- Melanoma4 studies
- Kidney Cancer (Renal Cell Carcinoma)4 studies
From ClinicalTrials.gov, data retrieved Oct 5, 2026. Each study sets its own eligibility; the study team decides who can join.